药物类过敏反应发生机制及临床前评价方法研究进展

发布时间：2018-06-26 19:00

本文选题：类过敏反应 + 发生机制　；参考：《中国新药杂志》2017年01期

【摘要】：药物类过敏反应是临床常见不良反应,中药注射剂、造影剂(RCM)、脂质体药物(如阿霉素,两性霉素,柔红霉素等)、两亲脂性胶束溶剂(如聚氧乙烯蓖麻油,紫杉醇载体等)、麻醉药、抗生素、镇痛药和止血剂等均可引起类过敏反应。然而,目前对类过敏反应产生的机制尚不完全清楚,现有的方法对预测药物类过敏反应仍存在不同程度的局限性。迄今为止,国内外均未建立类过敏反应的检测模型,亦缺少有关类过敏反应评价的技术指导原则,药物类过敏反应的评价受到了很大限制。因此,寻找评价类过敏反应的试验模型及其评价指标,合理有效地评价类过敏反应,从而实现对药物质量的控制,是目前急需解决的问题。本文从类过敏的发生机制、体内外评价模型及评价指标等方面对类过敏反应的研究进展作一综述,为其进一步研究提供参考。
[Abstract]:Drug allergic reactions are common adverse effects in clinical practice, such as Chinese traditional medicine injection, contrast agent (RCM), liposome drugs (such as adriamycin, amphotericin, daunorubicin, etc.), amphiphilic micelle solvents (such as polyoxyethylene castor oil, etc.). Paclitaxel carriers, anesthetics, antibiotics, analgesics and hemostatic agents can cause allergic reactions. However, the mechanism of anaphylactic reactions is not fully understood, and the existing methods still have different limitations in predicting drug allergic reactions. Up to now, there is no model for the detection of anaphylactic reactions at home and abroad, and there is also a lack of technical guidelines for the evaluation of anaphylactic reactions. The evaluation of drug allergic reactions has been greatly restricted. Therefore, it is urgent to find the experimental model and its evaluation index to evaluate the allergic reaction reasonably and effectively so as to control the drug quality. In this paper, the mechanism of anaphylactic reaction, the evaluation model in vitro and in vivo and the evaluation index are reviewed, which provides a reference for the further study of anaphylactic reaction.
【作者单位】：中国食品药品检定研究院国家药物安全评价监测中心药物非临床安全评价研究北京市重点实验室;中山大学药学院;
【基金】：国家重大新药创制科技重大专项资助项目(2012ZX09302001,2015ZX0901004-002)
【分类号】：R593.1

【相似文献】